The severity of MS, treatment, and lifestyle factors like smoking can influence life expectancy for people with MS. MS itself is not fatal, but complications from the disease may shorten lifespan.
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results